1. Home
  2. ABTC vs DRTS Comparison

ABTC vs DRTS Comparison

Compare ABTC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABTC

American Bitcoin Corp.

HOLD

Current Price

$0.93

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$10.72

Market Cap

978.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABTC
DRTS
Founded
2024
2015
Country
United States
Israel
Employees
2
121
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
978.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ABTC
DRTS
Price
$0.93
$10.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$4.00
$8.67
AVG Volume (30 Days)
11.3M
1.1M
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$79.69
N/A
Revenue Next Year
$50.64
$699.98
P/E Ratio
$5.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$2.85
52 Week High
$10.24
$11.62

Technical Indicators

Market Signals
Indicator
ABTC
DRTS
Relative Strength Index (RSI) 35.79 58.00
Support Level $0.93 $6.59
Resistance Level $1.25 $11.62
Average True Range (ATR) 0.07 1.00
MACD -0.02 -0.09
Stochastic Oscillator 11.10 65.94

Price Performance

Historical Comparison
ABTC
DRTS

About ABTC American Bitcoin Corp.

American Bitcoin Corp is a Bitcoin accumulation platform that integrates scaled Bitcoin mining operations with disciplined accumulation strategies. Its business is engaged in the operation of application-specific integrated circuit ("ASIC") miners for mining Bitcoin and the strategic accumulation of a Bitcoin reserve.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: